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Abstract: BACKGROUND Newborns delivered by elective cesarean section (CS) are at higher respi-
ratory risk than those delivered vaginally or by CS proceeded by labor (secondary CS). The oxytocin
challenge test (OCT) induces uterine contractions that trigger the release of fetal hormones regulating
lung fluid clearance during transition from the uterine to an air-breathing environment. OBJECTIVES
The aim is to summarize current evidence and outline the Lacarus trial protocol. METHODS Litera-
ture review informed the design of a randomized placebo-controlled multicenter trial of OCT preceding
elective CS in 1,450 women with a singleton pregnancy due for CS at >35 weeks gestation, without
preceding contractions, rupture of the membranes, or antenatal steroids. OCT comprises the infusion
of oxytocin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubling every 10 min until inducing 5
uterine contractions per 15-min interval. The primary endpoint is the occurrence of neonatal respiratory
morbidity within 24 h after birth. Secondary endpoints include biochemical and physiological parameters
of fetal and maternal well-being, such as breastfeeding rate and fetal plasma copeptin concentrations.
CONCLUSION This is the first trial to test the hypothesis that oxytocin-induced contractions before
elective CS is a promising application of physiologic principles gleaned from natural birth to improve
neonatal and maternal outcomes.
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Abstract
Background: Newborns delivered by elective cesarean sec-
tion (CS) are at higher respiratory risk than those delivered 
vaginally or by CS proceeded by labor (secondary CS). The 
oxytocin challenge test (OCT) induces uterine contractions 
that trigger the release of fetal hormones regulating lung 
fluid clearance during transition from the uterine to an air-
breathing environment. Objectives: The aim is to summarize 
current evidence and outline the Lacarus trial protocol. 
Methods: Literature review informed the design of a ran-
domized placebo-controlled multicenter trial of OCT pre-
ceding elective CS in 1,450 women with a singleton preg-
nancy due for CS at >35 weeks gestation, without preceding 
contractions, rupture of the membranes, or antenatal ste-
roids. OCT comprises the infusion of oxytocin 5 IU/500 mL 
Ringer lactate at a rate of 12 mL/h, doubling every 10 min 
until inducing 5 uterine contractions per 15-min interval. The 
primary endpoint is the occurrence of neonatal respiratory 
morbidity within 24 h after birth. Secondary endpoints in-
clude biochemical and physiological parameters of fetal and 
maternal well-being, such as breastfeeding rate and fetal 
plasma copeptin concentrations. Conclusion: This is the first 
trial to test the hypothesis that oxytocin-induced contrac-
tions before elective CS is a promising application of physi-
ologic principles gleaned from natural birth to improve neo-
natal and maternal outcomes. © 2021 The Author(s).
Published by S. Karger AG, Basel
Introduction
Elective cesarean section (CS) before the onset of labor 
or rupture of membranes, when compared to CS or vagi-
nal birth after the onset of labor, carries an increased risk 
of neonatal respiratory morbidity, including respiratory 
distress syndrome (RDS) or transient tachypnea of the 
Clinical trial registration: www.clinicaltrials.gov, NCT03693885.
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
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newborn [1, 2]. This is primarily thought to be due to an 
inadequate clearance of postnatal airway liquid in par-
ticular [3, 4]. Respiratory transition at birth comprises 3 
overlapping physiologic processes inextricably linked to 
labor (Fig. 1). First, uterine contractions not only prepare 
the maternal body for birth but also support the fetus by 
compressing its lungs, which during gestation are filled 
with liquid essential for lung growth that must be cleared 
from the airways at birth to allow air entry [5]. Uncleared 
liquid increases the time to aeration and causes respira-
tory morbidity [6]. Second, infant inspiration increases 
transpulmonary hydrostatic pressure gradients resulting 
in rapid airway liquid clearance into surrounding inter-
stitial tissue and establishing functional residual capacity 
within a few minutes [7]. Third, in a final step supported 
by stress hormone-induced activation of epithelial Na+ 
channels leading to transepithelial Na+ uptake [8] which 
concurrently leads to osmotic liquid absorption. Finally, 
liquid in the interstitial lung tissue is resorbed over the 
next hours via the lymphatics and vasculature [9].
Vaginal delivery of a healthy newborn provokes a 
unique surge in stress hormone plasma concentrations 
incommensurable with child or adult levels measured in 
any other situation [10]. Plasma copeptin, a nonspecific 
but more sensitive stress indicator than cortisol [11], 
leads this surge after vaginal delivery [12]. It derives from 
the prohormone of arginine vasopressin (AVP), is se-
creted in equimolar amounts to AVP from the pituitary 
into the circulatory system, and outperforms AVP in 
terms of measurability convenience in the clinical setting 
[13]. In contrast, newborns delivered by elective CS with-
out preceding labor have low copeptin and AVP concen-
trations unless other stressors are present, including cho-
rioamnionitis and fetal growth restriction [10, 14]. In 
newborns delivered by CS after labor onset, copeptin 
concentrations fall between these 2 extremes [12, 15] 
(Fig. 1).
The oxytocin challenge test (OCT) has been a standard 
procedure for many decades in pregnancies with suspect-
ed placental insufficiency [16]. In a previous study, we 
showed that copeptin, a surrogate marker of plasma va-
sopressin, is markedly increased in the umbilical cord 
blood of infants exposed to OCT-induced contractions 



























Fig. 1. Scheme of the study hypothesis.
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We hypothesize that the mild uterine contractions in-
duced by OCT suffice to upregulate various fetal stress 
hormones that enhance primary adaptation to an air-
breathing environment. More particularly, there is evi-
dence that AVP itself, which we measure using its surro-
gate marker copeptin, specifically supports lung adapta-
tion, including alveolar fluid resorption and surfactant 
secretion [8, 17, 18].
Materials and Methods
Design
The prospective randomized placebo-controlled trial in wom-
en due for elective CS compares the effect on neonatal respiratory 
morbidity of OCT-induced mild contractions versus standard pre-
CS procedure.
Recruitment and Setting
Women are recruited in 4 Swiss obstetric units (University 
Hospital Zurich, University Hospital Basel, Kantonsspital Baden, 
Kantonsspital St. Gallen). The day before elective CS they are asked 
for their informed consent. Enrolment runs from August 2019 to 
January 2023.
Inclusion and Noninclusion Criteria
Inclusion Criteria
• Signed informed consent by women who understand the 
meaning and scope of the study.
• Singleton pregnancy ≥35 weeks.
• Elective CS.
• No preceding contractions or rupture of the membranes.
• No contraindication to oxytocin.
Maternal Noninclusion Criteria
• Known or suspected unwillingness to follow the protocol.
• Substance abuse (heroin, cocaine, amphetamine, etc.)
• Placenta previa.
• Clinical signs of infection.
• Receiving treatment for arterial hypertension (any cause).
• Preeclampsia.
• Diabetes type I or II.
• Steroid therapy during pregnancy.
• Betablocker therapy at inclusion.
• Antenatal steroid administration for lung maturation.




• Intrauterine growth retardation.
• Nonreassuring fetal heart rate pattern.
Randomization
Women are randomized 1:1 using the secuTrial® electronic 
data capture system to infusion of either oxytocin (OCT group) or 
Ringer lactate (placebo group).
Sample Size
Sample size was estimated from our earlier study [15] and the 
retrospective neonatal respiratory morbidity rates published by De 
Luca et al. [1]. According to the Swiss Federal Statistical Office, the 
rate of cesarean section in Switzerland was 32.1% in 2018. A 
2-sample z-test for proportions computed in R (Version 3.0.3) re-
vealed that a reduction in the probability of respiratory distress 
from 5.5% (control group) to 3% (OCT group), given 750 women 
per group (total 1,500) and a 5% significance level, produces a 
power of 67%.
A sample size of 734 is needed per group to estimate the 95% 
confidence interval for the unknown probability of respiratory dis-
tress with precision of 0.0165 (1.65%). We perform all analyses in 
STATA 15.0 software (Stata Corporation, College Station, TX, 
USA) using the Mann-Whitney test and χ2 test or Fisher’s exact 
test, as appropriate, to compare groups at a 5% significance level. 
The trial is registered at https://clinicaltrials.gov/ under the iden-
tification code NCT03693885.
Intervention Procedure
After admission to the delivery room and placement of an in-
travenous line, women allocated to the OCT group receive oxyto-
cin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubled every 
10 min until it induces 5 uterine contractions per 15-min interval 
recorded with the cardiotocogram, at which point infusion is dis-
continued. The time interval between discontinuation of the OCT 
infusion and delivery can be between 30 and 240 min.
Arterial cord blood samples are collected immediately after de-
livery into EDTA tubes and centrifuged. Plasma aliquots are stored 
at −80°C. Copeptin is measured in 3 batches using the BRAHMS 
KRYPTOR automated research sandwich immunoluminometric 
assay (B·R·A·H·M·S C-terminal pro-AVP luminescence immuno-
assay; B·R·A·H·M·S AG, Hennigsdorf, Germany), as previously de-
scribed [19]. Infant stool and fresh breast milk samples taken by 
nurses and parents are stored at −20°C. DNA will be extracted us-
ing a commercial kit, and 16 S rRNA gene sequencing will be per-
formed to characterize bacterial composition.
Measurements and Outcomes
Primary Outcome
The primary endpoint is the difference in respiratory 
morbidity rate between infants in the OCT and control 
groups characterized by one or more of the following cri-
teria: tachypnea (>60 breaths per minute), expiratory 
grunting, chest wall retraction, flaring of the nostrils, cya-
nosis, need for oxygen, or any positive pressure support 
present for ≥2 h within the first 48 h after birth. Equiva-
lent diagnoses include RDS and transient tachypnea of 
the newborn.
Positive pressure support includes continuous posi-
tive airway pressure, high-flow nasal cannula, or me-
chanical ventilation. Neonatal death within 48 h after de-





The following secondary outcomes will be analyzed:
• Neonatal intensive care unit admission within 48 h ir-
respective of diagnosis.
• Fetal stress parameters: copeptin and pH in arterial 
umbilical cord blood.
• Duration of exclusive breastfeeding (<10 isolated for-
mula feedings are included).
• Duration of total breastfeeding (day of last breastfeed-
ing).
• Postnatal weight change and maximal postnatal weight 
loss.
• Bilirubin measured at least once in blood or by trans-
cutaneous bilirubinometry during the postnatal hos-
pital stay.
• Maternal total blood loss.
• Retrospectively: antibiotic use in pregnancy (when 
and for how long).
• Prospectively: antibiotic use postpartum (when and 
which).
• Infant weight, length, and BMI to 1 year.
• Antibiotic use in pregnancy and first year of infant’s 
life.
• Breast milk and infant stool samples collected and bio-
banked for end-of-study microbiome analysis.
Visit Schedule
Screening
Eligible women are asked for their informed consent 
at the latest on the day before elective CS or at the initial 
booking consultation.
Day of Elective CS
Women providing informed consent are randomized 
to the OCT or control group. Vital parameters (heart rate, 
blood pressure, and body temperature) are monitored 
pre-infusion in both groups.
Postnatal Ward (days 1–5 after Elective CS)
First infant stool sample, postnatal days 1–2.
Second infant stool sample, postnatal days 3–5.
Breast milk sample, postnatal days 3–5.
As recommended by the Swiss Society of Pediatrics, 
every child has a health booklet documenting its birth and 
preventive medical checkup data. We contact the parents 
by phone for their child’s weight and length at 4 weeks 
and their breastfeeding status at 12 months. We also ask 
about antibiotic treatments (name, number of episodes, 
and treatment duration).
Enrolment, Randomization, and Allocation 
Concealment
Women meeting all the inclusion criteria, including 
provision of informed consent, are reported to the trial 
center via secuTrial on the day of elective CS to receive a 
unique enrolment number followed by centralized block 
randomization using the secuTrial random number gen-
erator in a 1:1 ratio. Sequences of patient numbers are as-
signed to each center and kept confidential. The study 
medication (oxytocin or Ringer lactate) is randomly as-
signed to each patient number. The randomization docu-
mentation (“key list”) is monitored. Treatment allocation 
is available to the study assistant responsible for the inter-
vention. Neither parents, obstetricians nor neonatolo-
gists are aware of the treatment allocated.
Dropout Criteria
Oxytocin is not infused or infusion is stopped if a 
woman so requests, withdraws her consent and/or suffers 
painful contractions, or the fetal heart rate becomes ab-
normal.
Minimizing Bias
The effect of oxytocin is too evident for full blinding to 
be useful. Moreover, the study assistant in charge of the 
OCT must be unblinded for the oxytocin titration to 
achieve its target result: 5 contractions within 15 min. In 
our earlier study, only 55% of women noticed the uterine 
contractions, none of which were painful. Not only is the 
neonatologist assessing the primary endpoint (respira-
tory morbidity) uninvolved in antenatal obstetric inter-
vention, but study procedures and examination of the in-
fant are separated in time and space, meaning that the 
primary endpoint rater is effectively blinded to the inter-
vention.
Discussion
For over 20 years, antenatal corticosteroid (ANCS) ad-
ministration in pregnancies at risk of preterm delivery 
(<34 completed weeks of gestation) has been an important 
evidence-based practice for reducing RDS and mortality 
rates [20]. In late preterm infants (34–36 weeks), ANCS 
lowers neonatal respiratory morbidity irrespective of de-
Contractions before Elective Cesarean 
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livery mode but is only effective in term infants (≥37 
weeks) after elective CS, not after vaginal delivery [21, 22]. 
Offsetting this benefit was an unexpected significant in-
crease in neonatal hypoglycemia after ANCS treatment in 
late preterm infants. Due to the paucity of long-term safe-
ty data in late preterm and term infants, caution is needed 
before implementing ANCS routinely in pregnant women 
beyond 34 completed weeks of gestation [23, 24].
Oxytocin has long-standing indications in obstetrics 
and is approved by the FDA and EMA for antepartum 
and postpartum care, including the initiation or improve-
ment of uterine contractions, where this is desirable and 
considered suitable, for example, for a trial of labor after 
prior CS (TOLAC) [25], to control postpartum hemor-
rhage [26].
In contrast to TOLAC where oxytocin is given in high 
doses with the intention to initiate or augment birth-ef-
fective labor, OCT doses are much lower as the aim is to 
induce mild to moderate labor sufficient to assess placen-
tal efficiency [15]. Recently, we found that copeptin is sig-
nificantly increased in the umbilical cord blood of neo-
nates exposed to OCT-induced contractions before elec-
tive CS, with no adverse effects [15]. Although mild, such 
contractions suffice to upregulate fetal stress hormones 
that may help to improve primary adaptation to an air-
breathing environment [10]. In contrast to ANCS treat-
ment, which directly alters the fetal stress hormone re-
sponse and thus only influences the last phase of respira-
tory transition at birth, mild OCT-induced contractions 
have the potential to influence all 3 phases of the respira-
tory transition at birth in a positive and synergistic fash-
ion (Fig. 1).
Since any disturbance of the postnatal bonding period 
adversely affects motherhood, including lactation and 
breastfeeding, all measures supporting early skin-to-skin 
contact and avoiding division of the mother-infant dyad 
are welcome [27]. Lowering the incidence of neonatal re-
spiratory morbidity helps preserve the dyad and thus in-
crease the likelihood of successful lactation and breast-
feeding [28]. The key hormone in mammalian parenting 
and social development is oxytocin [29]. Where delivery 
occurs in the absence of labor, as in elective CS, endoge-
nous oxytocin has limited action, thus endangering the 
natural development of motherhood [30]. Current CS 
practice includes the administration of synthetic oxytocin 
to all mothers immediately after delivery to control post-
partum hemorrhage [26]. We conclude that given the 
current rates of elective CS and the excellent safety profile 
of OCT, the induction of mild contractions with oxytocin 
before elective CS may be a promising application of 
physiologic principles gleaned from natural birth to im-
prove neonatal and maternal outcomes.
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